Zealand Pharma announces positive results from the Phase 2 trial of glepaglutide in adult patients with short bowel syndrome (SBS). Glepaglutide is a novel longacting GLP-2 analogue invented and fully owned by Zealand. The trial was initiated in 2016 at Rigshospitalet, University of Copenhagen, Denmark, and the aim was to assess the efficacy, safety and … Continue reading Positive clinical trial result from Zealand Pharma